Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 16/20 | 0.53 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL990045 | 0.90 | GRM5 (0.54) | GRM5 | |
| SCHEMBL990246 | 0.88 | GRM5 (0.58) | GRM5 | |
| SCHEMBL990042 | 0.87 | GRM5 (0.52) | GRM5 | |
| SCHEMBL5741401 | 0.85 | GRM5 (0.52) | GRM5KMT2A | |
| SCHEMBL990810 | 0.84 | ALDH1A1 (0.48) | GRM5MEN1GAAKMT2ACHRM5 | |
| SCHEMBL990781 | 0.84 | ALDH1A1 (0.48) | GRM5MEN1GAAKMT2ACHRM5 | |
| SCHEMBL3627130 | 0.84 | GRM5 (0.58) | GRM5NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL990768 | 0.83 | GRM5 (0.47) | GRM5CHRM5 | |
| SCHEMBL990890 | 0.83 | GRM5 (0.47) | GRM5CHRM5 | |
| SCHEMBL990772 | 0.83 | GRM5 (0.60) | GRM5NPC1RAB9AMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080146647-A1 | ACETYLENE DERIVATIVES HAVING MGLUR 5 ANTAGONISTIC ACTIVITY | NOVARTIS AG (CH) | 2008-06-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080146647-A1 | ACETYLENE DERIVATIVES HAVING MGLUR 5 ANTAGONISTIC ACTIVITY | GRM5, GRIK5, GRM1 | GRM5 1/4885NPC1 1197/4885RAB9A 726/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.